Novo Holdings to acquire Altasciences

23 February 2021

Danish life sciences investor Novo Holdings announced that it has agreed to acquire Altasciences from Audax Private Equity.

Founded in 1992, Altasciences is a leading, fully-integrated, early drug development services platform, providing the pharma and biotech industries with a trusted partner for drug development, from pre-clinical safety testing through clinical proof-of-concept studies.

In the past decade, the company has grown both organically and through acquisitions to have a significant presence in the pre-clinical safety testing, clinical pharmacology, bioanalytical, CRO services, and CDMO markets. Headquartered in Laval, Canada, Altasciences operates six facilities in the USA and Canada and employs over 1,300 people.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK